Get started
Acrivon Therapeutics, Inc.Acrivon Therapeutics, Inc.Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

ACRV chart


Full chart

ACRV upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪47.03 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.44 USD
Net income (FY)
‪−80.56 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪21.74 M‬
Beta (1Y)
2.29

Employees


Employees (FY)
78
Change (1Y)
+20 +34.48%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.03 M‬ USD

About Acrivon Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Peter Blume-Jensen
Website
acrivon.com
Headquarters
Watertown
Founded
2018
FIGI
BBG011RWR2Q4
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ACRV news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as ACRV.

Frequently Asked Questions


The current price of ACRV is 2.15 USD — it has increased by 18.68% in the past 24 hours. Watch Acrivon Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Acrivon Therapeutics, Inc. stocks are traded under the ticker ACRV.
ACRV stock has risen by 19.48% compared to the previous week, the month change is a −65.70% fall, over the last year Acrivon Therapeutics, Inc. has showed a −79.72% decrease.
We've gathered analysts' opinions on Acrivon Therapeutics, Inc. future price: according to them, ACRV price has a max estimate of 19.00 USD and a min estimate of 7.00 USD. Watch ACRV chart and read a more detailed Acrivon Therapeutics, Inc. stock forecast: see what analysts think of Acrivon Therapeutics, Inc. and suggest that you do with its stocks.
ACRV reached its all-time high on Feb 6, 2023 with the price of 25.47 USD, and its all-time low was 1.30 USD and was reached on Apr 9, 2025. View more price dynamics on ACRV chart.
See other stocks reaching their highest and lowest prices.
ACRV stock is 46.00% volatile and has beta coefficient of 2.29. Track Acrivon Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Acrivon Therapeutics, Inc. there?
Today Acrivon Therapeutics, Inc. has the market capitalization of ‪47.03 M‬, it has decreased by −17.26% over the last week.
Yes, you can track Acrivon Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Acrivon Therapeutics, Inc. is going to release the next earnings report on May 13, 2025. Keep track of upcoming events with our Earnings Calendar.
ACRV earnings for the last quarter are −0.60 USD per share, whereas the estimation was −0.66 USD resulting in a 9.59% surprise. The estimated earnings for the next quarter are −0.66 USD per share. See more details about Acrivon Therapeutics, Inc. earnings.
Acrivon Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ACRV net income for the last quarter is ‪−22.83 M‬ USD, while the quarter before that showed ‪−22.44 M‬ USD of net income which accounts for −1.74% change. Track more Acrivon Therapeutics, Inc. financial stats to get the full picture.
No, ACRV doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has 78 employees. See our rating of the largest employees — is Acrivon Therapeutics, Inc. on this list?
Like other stocks, ACRV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Acrivon Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Acrivon Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Acrivon Therapeutics, Inc. stock shows the sell signal. See more of Acrivon Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.